Most recently, the drug pulled around 13.3 billion Japanese yen ($87 million) in the third quarter of Eisai’s 2024 fiscal year, which will end March 31. Leqembi collected sales of 29.6 billion ...

According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.

Sales of lecanemab (Leqembi), an FDA-approved Alzheimer’s drug, have climbed since 2023, despite questions about its effectiveness in women after Phase 3 trials showed limited benefit for females. A ...

Sales of Leqembi (lecanemab), a drug that targets Alzheimer’s disease, have been climbing steadily since its approval by the U.S. Food and Drug Administration (FDA) in 2023. In the last quarter ...